ProShare Advisors’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $239K | Sell |
25,357
-20,774
| -45% | -$186K | ﹤0.01% | 1544 |
|
|
2026
Q1 | $376K | Sell |
46,131
-5,579
| -11% | -$50.6K | ﹤0.01% | 1212 |
|
|
2025
Q4 | $347K | Buy |
51,710
+3,532
| +7% | +$26.6K | ﹤0.01% | 1366 |
|
|
2025
Q3 | $418K | Sell |
48,178
-5,260
| -10% | -$40.9K | ﹤0.01% | 1217 |
|
|
2025
Q2 | $337K | Sell |
53,438
-7,164
| -12% | -$47.4K | ﹤0.01% | 1369 |
|
|
2025
Q1 | $388K | Sell |
60,602
-10,386
| -15% | -$85.9K | ﹤0.01% | 1236 |
|
|
2024
Q4 | $571K | Buy |
70,988
+22,051
| +45% | +$213K | ﹤0.01% | 1194 |
|
|
2024
Q3 | $618K | Buy |
48,937
+12,330
| +34% | +$159K | ﹤0.01% | 1014 |
|
|
2024
Q2 | $463K | Sell |
36,607
-596
| -2% | -$6K | ﹤0.01% | 1024 |
|
|
2024
Q1 | $178K | Buy |
37,203
+8,570
| +30% | +$39.7K | ﹤0.01% | 1699 |
|
|
2023
Q4 | $137K | Buy |
28,633
+7,609
| +36% | +$46.6K | ﹤0.01% | 1731 |
|
|
2023
Q3 | $152K | Buy |
21,024
+573
| +3% | +$4.58K | ﹤0.01% | 1545 |
|
|
2023
Q2 | $152K | Buy |
+20,451
| New | +$161K | ﹤0.01% | 1608 |
|
|
2022
Q3 | – | Sell |
-7,365
| Closed | -$379K | – | 1791 |
|
|
2022
Q2 | $379K | Sell |
7,365
-2,183
| -23% | -$113K | ﹤0.01% | 1081 |
|
|
2022
Q1 | $703K | Sell |
9,548
-2,997
| -24% | -$267K | ﹤0.01% | 1076 |
|
|
2021
Q4 | $1.79M | Sell |
12,545
-5,131
| -29% | -$882K | ﹤0.01% | 792 |
|
|
2021
Q3 | $3.66M | Buy |
17,676
+1,897
| +12% | +$418K | 0.01% | 576 |
|
|
2021
Q2 | $3.35M | Sell |
15,779
-10,808
| -41% | -$1.98M | 0.01% | 591 |
|
|
2021
Q1 | $4.82M | Buy |
26,587
+2,050
| +8% | +$409K | 0.02% | 471 |
|
|
2020
Q4 | $2.74M | Buy |
24,537
+16,006
| +188% | +$1.7M | 0.01% | 562 |
|
|
2020
Q3 | $924K | Buy |
8,531
+619
| +8% | +$75.4K | ﹤0.01% | 745 |
|
|
2020
Q2 | $659K | Buy |
+7,912
| New | +$303K | ﹤0.01% | 834 |
|
|
2019
Q2 | – | Sell |
-8,575
| Closed | -$94K | – | 1646 |
|
|
2019
Q1 | $94K | Buy |
8,575
+78
| +0.9% | +$2.46K | ﹤0.01% | 1580 |
|
|
2018
Q4 | $313K | Sell |
8,497
-1,636
| -16% | -$63.4K | ﹤0.01% | 1129 |
|
|
2018
Q3 | $381K | Sell |
10,133
-398
| -4% | -$11.2K | ﹤0.01% | 1237 |
|
|
2018
Q2 | $282K | Buy |
10,531
+1,062
| +11% | +$35.9K | ﹤0.01% | 1414 |
|
|
2018
Q1 | $398K | Sell |
9,469
-1,298
| -12% | -$52.1K | ﹤0.01% | 1189 |
|
|
2017
Q4 | $267K | Buy |
10,767
+1,515
| +16% | +$37K | ﹤0.01% | 1462 |
|
|
2017
Q3 | $211K | Buy |
9,252
+459
| +5% | +$10.3K | ﹤0.01% | 1273 |
|
|
2017
Q2 | $202K | Sell |
8,793
-307
| -3% | -$6.02K | ﹤0.01% | 1342 |
|
|
2017
Q1 | $233K | Sell |
9,100
-2,223
| -20% | -$61.1K | ﹤0.01% | 1374 |
|
|
2016
Q4 | $285K | Buy |
11,323
+1,250
| +12% | +$36.5K | ﹤0.01% | 1396 |
|
|
2016
Q3 | $419K | Sell |
10,073
-2,106
| -17% | -$272K | 0.01% | 1020 |
|
|
2016
Q2 | $1.77M | Buy |
12,179
+242
| +2% | +$27.7K | 0.02% | 552 |
|
|
2016
Q1 | $1.23M | Sell |
11,937
-1,370
| -10% | -$147K | 0.02% | 627 |
|
|
2015
Q4 | $2.23M | Buy |
13,307
+1,256
| +10% | +$193K | 0.03% | 470 |
|
|
2015
Q3 | $1.7M | Sell |
12,051
-348
| -3% | -$78K | 0.02% | 521 |
|
|
2015
Q2 | $2.76M | Buy |
12,399
+456
| +4% | +$80.2K | 0.04% | 409 |
|
|
2015
Q1 | $1.98M | Buy |
11,943
+1,490
| +14% | +$242K | 0.02% | 565 |
|
|
2014
Q4 | $1.24M | Sell |
10,453
-418
| -4% | -$43.7K | 0.01% | 758 |
|
|
2014
Q3 | $907K | Sell |
10,871
-581
| -5% | -$52.5K | 0.01% | 1107 |
|
|
2014
Q2 | $1.06M | Sell |
11,452
-5,953
| -34% | -$523K | 0.01% | 1130 |
|
|
2014
Q1 | $1.58M | Buy |
17,405
+12,137
| +230% | +$1.36M | 0.02% | 920 |
|
|
2013
Q4 | $539K | Sell |
5,268
-1,946
| -27% | -$137K | 0.01% | 1062 |
|
|
2013
Q3 | $456K | Buy |
7,214
+1,538
| +27% | +$86.6K | 0.01% | 1547 |
|
|
2013
Q2 | $233K | Buy |
+5,676
| New | +$246K | ﹤0.01% | 1915 |
|
Other funds holding NVAX
SCM
S
ProShare Advisors's NVAX Position: Q2 2026 in Review
ProShare Advisors reduced its Novavax (NVAX) stake by 45% in Q2 2026, selling an estimated $186K and leaving 25,357 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #1544.
ProShare Advisors first reported a position in NVAX in Q2 2013 and has held it in 46 quarters since. The position peaked at $4.82M in Q1 2021. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.
- ProShare Advisors held 25,357 shares of Novavax worth $239K as of Q2 2026.
- ProShare Advisors sold 20,774 Novavax shares in Q2 2026, an estimated $186K.
- Novavax made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1544 holding.
- ProShare Advisors first reported a position in Novavax in Q2 2013 and has held it in 46 quarters since.
- ProShare Advisors's Novavax position peaked at $4.82M in Q1 2021.
- 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.